Capitainer’s self-sampling kit for examining COVID-19 antibody levels has revealed to be appropriate for clinical population testing.
The official quality criterion for accurate analysis resulting in clinical diagnosis was reached by ninety-seven per cent of the samples collected and returned to the lab by private individuals in a recent Swedish large scale population study.
“A self-sampling kit to examine COVID-19 antibody levels is appropriate for clinical population testing. “
CEO of Xerum, Julia Wigren Byström, stated: "Based on two-thousand and five hundred samples analysed so far, ninety per cent of the Capitainer cards delivered to the private individuals involved in the study were returned with an unprecedented ninety-seven per cent meeting the approved quality standard for analysis.”
CEO of Capitainer, Christopher Aulin, stated: “I am extremely happy to see the excellent performance of our self-sampling technology. We can now say with confidence that large scale population testing can be based on self sampling at home with our product. We have shown that clinical analysis of antibodies against the virus causing COVID-19 using samples collected on our cards works in a real-world setting. We envision a growing need for large-scale testing to ensure that the immunity created by the various vaccines protects against further spread of the disease and illness, especially since new mutations of the virus continue to emerge. We are currently building additional capacity for meeting these needs.”